PMDA — authorised 22 January 2021
- Marketing authorisation holder: Eli Lilly Japan K.K.
- Status: approved
PMDA authorised Emgality on 22 January 2021
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. PMDA authorised it on 22 January 2021; PMDA has authorised it.
Eli Lilly Japan K.K. holds the Japanese marketing authorisation.